Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the... see more

NDAQ:LEXX - Post Discussion

Lexaria Bioscience Corp > DehydraTECH lowers Blood Pressure in Human Study
View:
Post by Yowza123 on Jul 29, 2021 9:47am

DehydraTECH lowers Blood Pressure in Human Study

https://ir.lexariabioscience.com/news-events/press-releases/detail/145/lexarias-dehydratech-cbd-lowers-blood-pressure
Comment by WakeUPP on Jul 29, 2021 9:50am
found the other guy who didn't actually read that (with the pumper guy on twitter lol) duh
Comment by ShatteredGlass on Aug 17, 2021 3:34pm
Nice to see that 300mg dose was good enough to produce those results for Hypertension. Would like to know if DehydraTECH works with other cannabinoids like CBN, CBG, CBC. About Human Study HYPER-H21-1 Human Study HYPER-H21-1 was conducted at a European medical research hospital. Twenty-four human volunteers aged 45-65 with otherwise untreated pre- or mild-hypertension were given either a single ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities